Apogee Therapeutics, Inc. 13D

The Fairmount funds and related individuals exited their Apogee Therapeutics stake in the September 3, 2026 AbbVie cash merger at $135.11 per share and report no ongoing ownership or activist intentions.

Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and principals Peter Evan Harwin and Tomas Kiselak have filed Amendment No. 7 to their Schedule 13D on Apogee Therapeutics, Inc. to report that, upon consummation of the September 3, 2026 cash merger with AbbVie’s subsidiary Andor LLC at $135.11 per share, all of their Apogee common and non‑voting common shares and related options were cashed out and they no longer beneficially own any securities of the company; they state no ongoing activist or governance intentions beyond noting director resignations and termination of a prior voting agreement in connection with the closing.

Filing Facts

CIK

1974640

Ticker

APGE

Form

13D

Source Type

fda

Accession

0001104659-26-105122

Alert Tier

8